Nutritional Strategies for Battling Obesity-Linked Liver Disease: the Role of Medical Nutritional Therapy in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Management

Current Obesity Reports, Journal Year: 2025, Volume and Issue: 14(1)

Published: Jan. 11, 2025

This narrative review explores the role of Medical Nutritional Therapy (MNT) in managing Metabolic-Associated Steatotic Liver Disease (MASLD), previously known as nonalcoholic fatty liver disease. It aims to examine effectiveness specific nutritional strategies preventing and treating this obesity-linked Emerging evidence underscores benefits Mediterranean diet, low-carbohydrate diets, intermittent fasting reducing fat, improving insulin sensitivity, mitigating inflammation. Supplementing with vitamin E, omega-3 acids, silymarin can potentially reduce fibrosis promote health. MNT is a key intervention for MASLD management, emphasizing dietary patterns, caloric restriction, nutraceutical supplementation. Integrating these lifestyle modifications, including regular physical activity, offers comprehensive approach metabolic outcomes patients MASLD. Further research needed refine personalize therapeutic interventions.

Language: Английский

---

Natural Bioactive Compounds in the Management of Type 2 Diabetes and Metabolic (Dysfunction)-Associated Steatotic Liver Disease

Pharmaceuticals, Journal Year: 2025, Volume and Issue: 18(2), P. 279 - 279

Published: Feb. 19, 2025

Type 2 diabetes (T2D) and metabolic (dysfunction)-associated steatotic liver disease (MASLD) affect a growing number of individuals worldwide. T2D MASLD often coexist substantially elevate the risk adverse hepatic cardiovascular clinical outcomes. Several common pathogenetic mechanisms are responsible for onset progression, including insulin resistance, oxidative stress, low-grade inflammation, among others. The latter can also be induced by gut microbiota its derived metabolites. Natural bioactive compounds (NBCs) have been reported their therapeutic potential in both MASLD. A large amount evidence obtained from trials suggests that like berberine, curcumin, soluble fibers, omega-3 fatty acids exhibit significant hypoglycemic, hypolipidemic, hepatoprotective activity humans may employed as adjunct therapy management. In this review, role most studied NBCs management is discussed, emphasizing recent supporting these compounds' efficacy safety. Also, prebiotics act against dysfunction modulating evaluated.

Language: Английский

---

Gut microbiota in patients with metabolic, dysfunction-associated steatotic liver disease

Current Opinion in Clinical Nutrition & Metabolic Care, Journal Year: 2025, Volume and Issue: unknown

Published: April 24, 2025

Purpose of review Metabolic dysfunction-associated steatotic liver disease (MASLD) is a highly prevalent condition that can progress to fibrosis, steatohepatitis, and hepatocellular carcinoma. This examines recent advances concerning the role gut microbiota in MASLD microbiota-focused interventions positively impact outcome. Recent findings Dysbiotic compromised barrier facilitate translocation microbial-associated molecular patterns harmful metabolites into portal circulation liver, where they exacerbate inflammatory fibrogenic processes. Conversely, other bacterial have protective effects liver. Therefore, homeostasis essential for maintaining health. Summary Levels including ethanol, NH 3 , trimethylamine-L-oxide, 2-oleylglycerol, litocholic acid are often increased patients with MASLD. short-chain fatty acids, indole derivatives, histidine, acids taurodeoxycholic, 3-succinylcholic, hyodeoxycholic decreased. The main aim current interventions/treatments reduce increase beneficial ones. These include drugs (pemafibrate, metformin, obeticholic acid), natural compounds (silymarin, lupeol, dietary fiber, peptides), exogenous bacteria (probiotics, symbionts), special diets (Mediterranean diet, time-restricted feeding), as well transplantation, phage therapy. Most improve permeability, inflammation, fibrosis through regulation, promising alternatives MASLFD management. However, most results come from animal studies, while clinical trials lacking. Further research therefore needed this area.

Language: Английский

---

A Comprehensive Review of Metabolic Dysfunction-Associated Steatotic Liver Disease: Its Mechanistic Development Focusing on Methylglyoxal and Counterbalancing Treatment Strategies

International Journal of Molecular Sciences, Journal Year: 2025, Volume and Issue: 26(6), P. 2394 - 2394

Published: March 7, 2025

Metabolic dysfunction-associated steatotic liver disease (MASLD) is a multifactorial disorder characterized by excessive lipid accumulation in the which dysregulates organ’s function. The key contributor to MASLD development insulin resistance (IR) affects many organs (including adipose tissue, skeletal muscles, and liver), whereas molecular background associated with oxidative, nitrosative, carbonyl stress. Among molecules responsible for stress effects, methylglyoxal (MGO) seems play major pathological MGO—a by-product of glycolysis, fructolysis, lipolysis (from glycerol fatty acids-derived ketone bodies)—is implicated hyperglycemia, hyperlipidemia, obesity, type 2 diabetes, hypertension, cardiovascular diseases. Its causative effect stimulation prooxidative proinflammatory pathways has been well documented. Since metabolic dysregulation leading these pathologies promotes MASLD, role MGO addressed this review. Potential participation mechanism discussed regard its different signaling routes events accelerating disorder. Moreover, treatment strategies including approved potential therapies are overviewed them, medications aimed at attenuating MGO-induced processes addressed.

Language: Английский

---

Flavonoids and Their Role in Preventing the Development and Progression of MAFLD by Modifying the Microbiota

International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(20), P. 11187 - 11187

Published: Oct. 17, 2024

With the increasing prevalence and serious health consequences of metabolic-associated fatty liver disease (MAFLD), early diagnosis intervention are key to effective treatment. Recent studies highlight important role dietary factors, including use flavonoids, in improving health. These compounds possess anti-inflammatory, antioxidant, liver-protective properties. Flavonoids have been shown affect gut microbiota, which plays a function progression. Therefore, their preventing development progression MAFLD through modulation microbiome seems be interest. This narrative review aims consolidate current evidence on effects selected flavonoids progression, potential mechanisms action, implications for personalized interventions management disease.

Language: Английский

---